Table 2 Relationship between preoperative SII/Ki-67 index and clinical data of prostate cancer patients in two groups
Parameters | SII low expression group (N = 145) | SII high expression group (N = 145) | P | Ki-67 low expression group (N = 145) | Ki-67 high expression group (N = 145) | P |
|---|---|---|---|---|---|---|
PSA (ng/mL) | ||||||
< 20 | 90 (62.07%) | 70 (48.28%) | 0.0182 | 89 (61.38%) | 71 (48.97%) | 0.0336 |
≥ 20 | 55 (37.93%) | 75 (51.72%) | 56 (38.62%) | 74 (51.03%) | ||
Gleason score | ||||||
< 8 | 76 (52.41%) | 81 (55.86%) | 0.5557 | 88 (60.69%) | 69 (47.59%) | 0.0251 |
≥ 8 | 69 (47.59%) | 64 (44.14%) | 57 (39.31%) | 76 (52.41%) | ||
T stage | ||||||
T2 | 65 (44.83%) | 60 (41.38%) | 0.5533 | 62 (42.76%) | 63 (43.45%) | 0.9056 |
T3-4 | 80 (55.17%) | 85 (58.62%) | 83 (57.24%) | 82 (56.55%) | ||
Lymph node metastasis | ||||||
No | 91 (62.76%) | 78 (53.79%) | 0.1216 | 93 (64.14%) | 76 (52.41%) | 0.0429 |
Yes | 54 (37.24%) | 67 (46.21%) | 52 (35.86%) | 69 (47.59%) | ||
Seminal vesicle invasion | ||||||
No | 78 (53.79%) | 83 (57.24%) | 0.5546 | 83 (57.24%) | 78 (53.79%) | 0.5546 |
Yes | 67 (46.21%) | 62 (42.76%) | 62 (42.76%) | 67 (46.21%) | ||
Neutrophils (× 109/L) | 2.84 ± 0.75 | 3.78 ± 0.71 | < 0.0001 | 3.34 ± 0.85 | 3.28 ± 0.89 | 0.5097 |
Lymphocytes (× 109/L) | 2.12 (1.25,3.25) | 1.48 (0.80,2.33) | < 0.0001 | 1.86 (0.80,3.25) | 1.68 (0.82,3.02) | 0.0042 |
Platelets (× 109/L) | 227.50 ± 25.73 | 251.80 ± 36.22 | < 0.0001 | 229.0 (163,355) | 242.0 (167,332) | 0.0336 |